Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Template:Current week ecosystem agenda"

From Bioblast
Line 1: Line 1:
  2021 Week 9
  2021 Week 10


*'''Mar-08 Mo'''
:::: Abstract submission deadline for: »[[ESCI 2021 Virtual]]«
----
*'''Mar-09 Tu''' - [[12th_%C3%96GMBT_Annual_Meeting_2020_Virtual_Event#Programme|ÖGMBT Life Science Tuesdays]]


*'''Mar-1 Mo'''  
----
 
*'''Mar-10 We'''
:{|
:{|
| width="100" align="center" |[[Image:O2k-Publications.jpg|70px|link=http://wiki.oroboros.at/index.php/O2k-Publications:_Topics |O2k-Publications in the MiPMap]]
| width="100" align="center" |[[File:MitoFit Preprints pdf.png|100px|link=https://www.mitofit.org/index.php/Krako_Jakovljevic_2021_MitoFit_PD |MitoFit pdf]]
|'''Complex I of the mitochondrial electron transfer system is an important druggable target in Alzheimer's disease'''<br>
|'''Mitochondrial physiology in Parkinson’s disease (PD)'''<br>
:from the O2k-Network »[[US NY New York Galkin A]]«
A [[MitoEAGLE|COST Action MitoEAGLE]] contribution:<br>
*Stojakovic A, Trushin S, Sheu A, Khalili L, Chang SY, Li X, Christensen T, Salisbury JL, Geroux RE, Gateno B, Flannery PJ, Dehankar M, Funk CC, Wilkins J, Stepanova A, O'Hagan T, Galkin A, Nesbitt J, Zhu X, Tripathi U, Macura S, Tchkonia T, Pirtskhalava T, Kirkland JL, Kudgus RA, Schoon RA, Reid JM, Yamazaki Y, Kanekiyo T, Zhang S, Nemutlu E, Dzeja P, Jaspersen A, Kwon YIC, Lee MK, Trushina E (2021) Partial inhibition of mitochondrial complex I ameliorates Alzheimer's disease pathology and cognition in APP/PS1 female mice. Commun Biol 4:61. [[Stojakovic 2021 Commun Biol|»Bioblast link«]]
* Krako Jakovljevic N, Ebanks B, Chakrabarti L, Markovic I, Moisoi N (2021) Mitochondrial homeostasis in cellular models of Parkinson’s Disease. MitoFit Preprints 2021.4 [https://www.mitofit.org/index.php/Krako_Jakovljevic_2021_MitoFit_PD doi:10.26124/mitofit:2021-0004]  
|}
|}
----
----
*'''Mar-2 Tu'''  
*'''Mar-11 Th'''  
 
:{|
:{|
| width="110" align="center" | [[File:MitoPedia.jpg|left|80px|MitoPedia|link=MitoPedia]]
| width="110" align="center" | [[File:Gnaiger 2020 BEC MitoPathways.jpg|70px|link=https://www.bioenergetics-communications.org/index.php/bec/article/view/gnaiger_2020_mitopathways|Gnaiger 2020 BEC MitoPathways]]
|''' Measuring fatty acid oxidation (FAO)-linked respiration requires a low concentration of malate '''<br>
| '''Internal normalization of rate  – what is the difference between ''flux control ratio'' and ''flux control efficiency''?'''<br>
In the absence of malate, accumulation of Acetyl-CoA inhibits FAO. <br>
A ''flux control ratio'' is the ratio of oxygen flux in a specific respiratory control state, normalized for maximum flux in a common reference state. ''Flux control efficiency'' expresses the control of respiration as a fractional change of oxygen flux or flow between protocol steps. Both values vary between theoretical lower and upper limits of 0 and 1. <br>
- »'''[[Fatty acid oxidation pathway control state]]'''«, »'''[https://www.bioblast.at/index.php/Gnaiger_2020_BEC_MitoPathways Mitochondrial Pathways: Chapter 5]'''« <br>
- »[https://www.bioenergetics-communications.org/index.php/bec/article/view/gnaiger_2020_mitopathways Gnaiger 2020 BEC MitoPathways - Chapter 3]« <br>
- communicated by »[[Cecatto Cristiane]]« and »[[Cardoso Luiza]]«  
- » Posted by: »[[Komlodi Timea]]« and »[[Cecatto Cristiane]]«
|}
|}
----
*'''Mar-3 We'''
:::: [[File:FAT4BRAIN logo.png|100px|FAT4BRAIN|link=FAT4BRAIN O2k-Workshop IOC148 Virtual Event]] <big>»'''[[FAT4BRAIN O2k-Workshop IOC148 Virtual Event]]'''«</big> (Mar 3-4)
----
*'''Mar-4 Th'''
----
----
*'''Mar-05 Fr'''
*'''Mar-12 Fr'''

Revision as of 12:38, 8 March 2021

2021 Week 10
  • Mar-08 Mo
Abstract submission deadline for: »ESCI 2021 Virtual«


  • Mar-10 We
MitoFit pdf Mitochondrial physiology in Parkinson’s disease (PD)

A COST Action MitoEAGLE contribution:

  • Krako Jakovljevic N, Ebanks B, Chakrabarti L, Markovic I, Moisoi N (2021) Mitochondrial homeostasis in cellular models of Parkinson’s Disease. MitoFit Preprints 2021.4 doi:10.26124/mitofit:2021-0004

  • Mar-11 Th
Gnaiger 2020 BEC MitoPathways Internal normalization of rate – what is the difference between flux control ratio and flux control efficiency?

A flux control ratio is the ratio of oxygen flux in a specific respiratory control state, normalized for maximum flux in a common reference state. Flux control efficiency expresses the control of respiration as a fractional change of oxygen flux or flow between protocol steps. Both values vary between theoretical lower and upper limits of 0 and 1.
- »Gnaiger 2020 BEC MitoPathways - Chapter 3« 
- » Posted by: »Komlodi Timea« and »Cecatto Cristiane«


  • Mar-12 Fr